Intellia Therapeutics (NASDAQ:NTLA) Receives New Coverage from Analysts at Bank of America

Bank of America started coverage on shares of Intellia Therapeutics (NASDAQ:NTLAGet Rating) in a research report issued to clients and investors on Thursday, The Fly reports. The firm set a “buy” rating on the stock.

Several other research firms have also issued reports on NTLA. JMP Securities decreased their price target on shares of Intellia Therapeutics from $165.00 to $110.00 in a research report on Monday, May 9th. Brookline Capital Management raised shares of Intellia Therapeutics from a “hold” rating to a “buy” rating and set a $91.00 price objective for the company in a report on Monday, March 7th. Credit Suisse Group started coverage on shares of Intellia Therapeutics in a report on Thursday, April 28th. They set an “outperform” rating and a $100.00 price objective for the company. William Blair started coverage on shares of Intellia Therapeutics in a report on Friday, February 18th. They set an “outperform” rating and a $144.00 price objective for the company. Finally, Brookline Capital Acquisition raised shares of Intellia Therapeutics from a “hold” rating to a “buy” rating and set a $91.00 price objective for the company in a report on Monday, March 7th. Two investment analysts have rated the stock with a hold rating and twenty have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $139.90.

NASDAQ:NTLA opened at $40.93 on Thursday. The firm has a market capitalization of $3.10 billion, a PE ratio of -8.14 and a beta of 2.15. The firm’s fifty day simple moving average is $50.11 and its 200 day simple moving average is $78.01. Intellia Therapeutics has a 1 year low of $37.08 and a 1 year high of $202.73.

Intellia Therapeutics (NASDAQ:NTLAGet Rating) last posted its quarterly earnings results on Thursday, May 5th. The company reported ($1.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.11) by ($0.85). The company had revenue of $11.30 million during the quarter, compared to analyst estimates of $8.57 million. Intellia Therapeutics had a negative return on equity of 41.00% and a negative net margin of 973.48%. The business’s revenue for the quarter was up 73.8% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.69) earnings per share. Equities analysts anticipate that Intellia Therapeutics will post -5.77 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently modified their holdings of NTLA. Reilly Financial Advisors LLC acquired a new position in Intellia Therapeutics during the fourth quarter valued at approximately $25,000. Paragon Capital Management Ltd bought a new position in Intellia Therapeutics in the fourth quarter valued at approximately $25,000. Prospera Financial Services Inc bought a new position in Intellia Therapeutics in the first quarter valued at approximately $32,000. National Bank of Canada FI bought a new position in Intellia Therapeutics in the fourth quarter valued at approximately $34,000. Finally, JNBA Financial Advisors bought a new position in Intellia Therapeutics in the fourth quarter valued at approximately $35,000. Hedge funds and other institutional investors own 85.89% of the company’s stock.

Intellia Therapeutics Company Profile (Get Rating)

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency.

Read More

The Fly logo

Analyst Recommendations for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.